BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 16033851)

  • 1. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
    Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA; Lebwohl D
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
    Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
    Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
    Zitzmann K; De Toni EN; Brand S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
    Neuroendocrinology; 2007; 85(1):54-60. PubMed ID: 17310129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Takaoka M; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
    Oncol Rep; 2010 Apr; 23(4):1167-72. PubMed ID: 20204306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letrozole sensitizes breast cancer cells to ionizing radiation.
    Azria D; Larbouret C; Cunat S; Ozsahin M; Gourgou S; Martineau P; Evans DB; Romieu G; Pujol P; Pèlegrin A
    Breast Cancer Res; 2005; 7(1):R156-63. PubMed ID: 15642164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
    Macedo LF; Guo Z; Tilghman SL; Sabnis GJ; Qiu Y; Brodie A
    Cancer Res; 2006 Aug; 66(15):7775-82. PubMed ID: 16885381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
    Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
    Sonne-Hansen K; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
    Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
    Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
    Tirado OM; Mateo-Lozano S; Notario V
    Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.